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Background.  The  innate  immune  system, including
complement  and natural  killer  (NK) cells, plays a crit-
ical  role  in  activation  and damage  of endothelial  cells
(ECs) during  xenograft  rejection.  The  semisynthetic
proteoglycan  analog  dextran  sulfate  (DXS, molecular
weight  5,000)  is known  to  inhibit  the  complement  and
coagulation  cascades. We hypothesized  that  DXS may
act as an "EC-protectant"  preventing  complement  and
NK  lysis  by  functionally  replacing  heparan  sulfate
proteoglycans  that  are shed  from  the  EC surface  on
activation  of the endothelium.
Methods.  Binding  of  DXS to  ECs, deposition  of hu-
man  complement,  cytotoxicity,  and  heparan  sulfate
expression  after  exposure  to  normal  human  serum
were  analyzed  by flow cytometry.  The  efficacy  of DXS
to  protect  ECs from  xenogeneic  NK cell-mediated  cy-
totoxicity  was tested  in standard  51Cr-release assays.
Results.  DXS  dose-dependently  inhibited  all  three
pathways  of complement  activation.  Binding  of DXS  to
porcine  cells  increased  on treatment  with  human  se-
rum  or heparinase  I and correlated  positively  with  the
inhibition  of human  complement  deposition.  This  cy-
toprotective  effect  of DXS was  still  present  when  the
challenge  with  normal  human  serum  was performed
up to 48 hr  after  DXS treatment  of the cells.  DXS incu-
bation  of  porcine  ECs with  and  without  prior  tumor
necrosis  factor-a  stimulation  reduced  xenogeneic  cy-
totoxicity  mediated  by human  NK  cells  by 47.3% and
25.3%,  respectively.
Conclusions.  DXS  binds  to porCine  cells Bcnd  protects
them  from complement-  and  NK cell-mediated  injury  in
vitro.  It  might  therefore  be used as a novel therapeutic
strategy  to  prevent  xenograft  rejection  and has poten-
tial  for  clinical  application  as an "EC protectant."
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One potential approach  to overcome  the shortage of  human
donor organs for transplantation  might be xenotransplanta-
tion using porcine organs.  However,  the immune response  to
such discordant xenografts forms  several hurdles  that are
difficult  to overcome.  The first  is the recipient's innate im-
munity,  which leads to hyperacute rejection  (HAR) of the
transplanted organ. Naturally  occurring xenoreactive anti-
bodies (XNAs) from the recipient's blood bind to antigens on
graft  endothelial cells (ECs)  and promote complement  acti-
vation, which in turn causes  injury and activation of  the graft
endothelium (1). Depletion ofXNAs  from the recipient's cir-
culation by immunoabsorption (2), depletion of complement
by cobra venom factor,  fluid-phase complement  inhibition  by
soluble recombinant complement  receptor 1 (3), and genetic
engineering of pigs to (over)express  human membrane-asso-
ciated  complement-regulatory  molecules  (CD46,  CD55,
CD59)  were effective in preventing  HAR in  pig-to-primate
models  (4). However, although HAR can be overcome,  xeno-
grafts  still  succumb to acute vascular rejection (A  VR), also
characterized by deposition  ofXNAs and complement  activa-
tion with  subsequent  EC activation and dysfunction. In ad-
dition, infiltration  of xenografts with leukocytes was noticed
during A  VR (5).  Various strategies are currently being tested
to prevent and treat A  VR; among others, the elimination of
the major xenoantigen Galal,3  Gal on porcine ECs by nu-
clear transfer technique is the most promising (6). In ham-
ster-  and  mouse-to-rat heterotopic  heart  transplantation
models,  A  VR can  be overcome  by transient  depletion of com-
plement with cobra  venom  factor in combination with contin-
uous administration  of cyclosporine A (7). Under these con-
ditions, the graft ECs are able to express protective genes
like HO-l,  A20, and Bcl-2,  enabling them to "accommodate,"
that  is, to survive despite the presence of EC-specific anti-
bodies and complement  (8,9).
In  addition  to the humoral  attack,  in vivo  and in vitro
studies of cellular pig-to-human interactions have identified
natural  killer  (NK) cells as an important  component  of the
innate immune response  toward xenografts (10,11). NKcells
are a lymphocyte subset  and are equipped with killer  immu-
noglobulin (lg)-like receptors that  deliver an inhibitory  sig-
nal  on  binding  to  self-major  histocompatibility  complex
(MHC) class I  molecules.  Cells that  do not bear self-MHC
class I  on the  surface, for  example, xenogeneic cells, are
susceptible to NK  cell-mediated lysis.  Moreover, little  is
known on the nature  of activating  ligands  present on the
surface of porcine target cells,  which trigger natural cytotox-
icity receptors on human NK cells (12). Nevertheless,  protec-
tion of the endothelium from both complement-  and NK cell-
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mediated  injury  seems to be  crucial  for  the  prevention  and
treatment  of A  VR.
Physiologically,  ECs  are  covered  with  a  layer  of heparan
sulfate  proteoglycan  (HSPG),  which  is  crucial  for the  antico-
agulant  and  anti-inflammatory  properties  of the  endothe-
lium.  As  shown  by  Platt  et  aI., HSPG  is  shed  from  the  cell
membrane  on activation  of ECs, exposing  a procoagulant  and
proinflammatory  cell surface  (13). We therefore  investigated
the  potential  of the  semisynthetic  glycosaminoglycan  analog
dextran  sulfate  (DXS) to replace  HSPG  and  thereby  to  pro-
tect  the  endothelium  from  damage  mediated  by complement
and  NK cells.  DXS is a sulfated,  linear  or  slightly  branched
polysaccharide  (14) and is  known  to  inhibit  the classic  path-
way  of complement  activation  by potentiation  ofCl-inhibitor
activity  and  by inhibition  of C3 and  C4 (15).  Moreover,  DXS
blocks the  alternative  pathway  of  complement  activation  by
interacting  with  the  poly anion  binding  site  of factor  H (16).
Recently,  we  showed  that  DXS  delays  HAR  in  ex vivo  xe-
noperfused  pig lungs  (17). In the  present  study,  we confirmed
our  hypothesis  by demonstrating  that  DXS binds  to porcine
cells  and  prevents  complement-  and  NK  cell-mediated  lysis
in  functional  in vitro  assays. Therefore,  DXS may be of use as
an  EC  protective  substance  in  xenotransplantation.
MATERIALS  AND  METHODS
Reagents
Low molecular weight (MW) DXS (MW 5000) (DXS, sodium salt,
order no. D-7037)  and heparinase (Heparinase I, H-2519)  were pur-
chased  from Sigma Chemical Company  (St. Louis, MO). Fluorescein-
labeled DXS (DXS-Fluo)  was prepared as  follows: DXS  was converted
to dimethyl formamide (Sigma) soluble form  (DXS-iPr~HEt+)  by
flash  ion-exchange chromatography on a  Dowex50 (H +)  column,
followed by neutralization  with  N,N-diisopropylethylamine  and ly-
ophilization. The free hydroxyl groups ofDXS were then activated by
adding  8 mg of 1,1'- carbonyldiimidazole  to a  solution of 200 mg
DXS-iPr~t+  in  2 mL of dimethyl  formamide and stirring  the
mixture  for 2 hr  at 45.C. After  that  time,  18 mg of dry fluorescein
cadaverine (Molecular Probes  Europe, Leiden, The Netherlands) was
added,  ~nd the mixture was  stirred  overnight at room  temperature.
DXS-Fluo was isolated using a LH-20 Sephadex column and aceto-
nitrile-water  (1:1) as eluent.  After  concentration of the  fractions
containing  DXS-Fluo, 50 mg of sodium bicarbonate in 5 mL water
was added,  and the  mixture was lyophilized.  Column chromatogra-
phy (acetonitrile-water, 1:1) of the residue on LH-20 Sephadex  gave
105 mg of DXS-Fluo. A substitution  rate of 1 mol-% was determined
by absorption measurement  at 492 nm, meaning that 1%  of the DXS
molecules were labeled. DXS-Fluo was tested for complement-inhib-
itory  activity  in standard hemolytic  assays for the classic, alterna-
tive,  and lectin pathways. The  complement inhibitory  activity  of
DXS-Fluo was slightly lower «10%)  compared with unlabeled DXS
with  identical shapes  of the inhibition  curves.
Buffers and Serum
The following buffers were used: veronal-buffered saline (pH 7.4:
1.8 mM Na-5,5-diethylbarbital,  0.2 mM  5,5-diethylbarbituric  acid,
145 mM NaCl), GVB (veronal-buffered saline containing 0.1% gela-
tin), DGVB (GVB diluted with an equal volume of 6% [w/v)  dextrose
solution), DGVB2+ (DGVB containing  0.15 mM Ca2+  and 0.5 mM
Mg2+), DGVB-MgEGTA (DGVB2+ containing  15 mM Mg2+  and 30
mM EGTA), phosphate-buffered saline (PBS) (0.1 M PBS, pH 7.4),
and fluorescence-activated  cell sorter (F  ACS) buffer (PBS  containing
1% bovine serum albumin and 0.02% NaNa). Normal human serum
(NHS) was obtained by centrifugation of blood  collected  from healthy
adult volunteers and stored in aliquots at -70.C  until use.
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Cell Isolation and Culture
Pig aortic ECs (PAECs)  were mechanically isolated from pig aor-
tas and cultured on fibronectin-coated tissue culture plates (Becton
Dickinson, Franklin Lakes,  NJ). PAECs  were grown until confluence
in  Dulbecco's Modified Eagle's Medium,  supplemented with  10%
fetal calf serum, 100 U/mL penicillin,  and 100 IJ.gtmL  streptomycin
(lnvitrogen Corporation, Carlsbad, CA). PAECs were used between
passages  two and four in all experiments. The pig kidney cell line
PK15 (American Type Cultu,re Collection, Manassas, VA) and the
SV40-immortalized porcine aorta-derived EC line PED (18) was cul-
tured under the same conditions as PAECs. The humim MHC class
I-deficient erythroleukemia cell line K562 and the NK cell line NK92
(19) were both obtained from American Type Culture Collection and
maintained in Roswell Park Memorial Institute,  10% fetal calf se-
rum, or MyeloCult H5100 medium (StemCeli Technologies,  Vancou-
ver, Canada) containing 500 U/mL of human interleukin-2 (Chiron,
Emeryville, CA),  respectively. All cell lines were regularly tested  for
mycoplasma  contamination by polymerase  chain reaction (Mycoplas-
ma Plus Polymerase Chain Reaction Primer  Set, Stratagene, Am-
sterdam, The Netherlands).
Hemolytic Assays (AP50, CH50, LP50)
Assays  for alternative (AP50),  classic  (CH50),  and lectin (LP50)  com-
plement pathway activities were modified versions of the  tests de-
scribed  earlier <20-22).  In  brief, 0.1 mL of rabbit erythrocytes  (for the
AP50 test, loa  cells/mL in  DGVB-MgEGTA) or antibody-sensitized
sheep  erythrocytes  (for the CHSO  test, loa celis/mL in DGVB2+,  coated
with  rabbit anti-sheep  red cell stroma antiserum from Sigma)  were
incubated  willi  0.1 mL of serum diluted in the appropriate  buffer and
incubated  for 60 min at 37.C in a shaking water bath. For llie LP50
test, 0.1 mL of diluted serum was incubated  in the same  way willi  0.1
mL ofa mixture of10S  celis/mL  chicken E, 0.3X107  cells/mL  Saccharo-
myces  cerevisiae  (baker's  yeast),  and 1.5%  mannose-binding  lectin-defi-
cient serum (Statens Serum Institut,  Copenhagen,  Denmark). After
adding 1.5 mL ice-cold  PBS and centrifugation for 7 min at 1750g,
hemolysis  was determined  in the supernatant by measuring  the absor-
bance of released  hemoglobin at  412 nm.  For  llie  100%  hemolysis
control, 1.5  mL of water was added  in place  ofPBS. Sheep  erythrocytes
were  purchased  from Biomerieux,  Marcy l'Etoile, France.  Rabbit  eryth-
rocytes  were obtained  from healthy Burgundy rabbits and stored in
Alsever  solution (Sigma)  until use. The rabbits were in-house  bred and
kept at the animal experimentation  facilities in the University Hospital
of Bern. The chickens  were from the farm of Hans Thiiler, Scheunen,
Switzerland. All animals received  humane care according  to national
and international guidelines.
Flow Cytometry
Pig cells (PK15 or PAEC; 0.5-1X105 cells/sample)  were suspended
in trypsin-EDTA, washed  twice in culture  medium, and then incu-
bated  with  different concentrations (0.04-25  mgtmL) of DXS for 30
min at 37.C. After three washing steps with  warm culture medium,
incubation of the DXS-treated and suspended  cells was continued
under normal conditions for  0 to 48 hr.  DXS-mediated protection
from complement activation on the  cell surface and complement-
mediated cytotoxicity was then tested by incubation of  the cells with
1:4  diluted NHS or heat-inactivated NHS (20 min at 56.C) for 45 min
at  37.C. After washing with cold FACS buffer, the cells were sequen-
tially incubated at 4.C for 30 min with saturating  concentrations of
first and second  antibodies. The following  antibody conjugates  were
used: goat anti-human IgG conjugated to fluorescein isothiocyanate
(FITC) and IgM-R-phycoerythrin conjugate (Sigma), rabbit anti-hu-
man C1q (gift from Professor  M.R. Daha, Leiden, The Netherlands),
rabbit anti-human  C3c and C4c (DAKO, Glostrup, Denmark), goat
anti-rabbit  IgG-FITC (Southern Biotechnology Associated,  Birming-
ham, AL), and goat anti-mouse IgG-FITC (Sigma). Cytotoxicity was
detected  by standard propidium-iodide  staining (Sigma). The samples
were then resuspended  in 1%  paraformaldehyde,  and the fluorescence840 TRANSPLANTATION Vol. 76,  No.5
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was measured using a FACSCalibur (Becton  Dickinson). Data were
analyzed  using the FlowJo  software  (Tree Star, San Carlos,  CA).
Binding of DXS-Fluo to Endothelial  Cells
To experimentally damage  or activate PAECs (release of HSPG),
the cells were trypsinized and then preincubated with  1:4 diluted
NHS for 30 min at 37°C (13). As a control for HSPG release,  PAECs
were also  treated for 1.5  hr at 37"C with 1 U/mL ofheparinase. After
incubation  with  various concentration of DXS-Fluo for  30 min  at
37°C, the cells were washed three times, and the fluorescence  was
measured by FACS. In parallel, the presence of HSPG on the cells
was determined with  biotinylated mouse anti-human  heparan sul-
fate  antibody (Seikagaku, Tokyo, Japan), followed by streptavidin
R-phycoerythrin conjugate  (Molecular Probes).
Natural  Killer  Cytotoxicity Assay
The cytotoxic  activity  of human  NK92 cells  against  PED was
tested in standard 51Cr-release  assays  as described previously (23).
Briefly,  unstimulated  or tumor necrosis factor (TNF)-a stimulated
(human TNF -a, Sigma, 1,000  U/mL for 12 hr at 37") PED target cells
were trypsinized and preincubated with  25 mg/mL DXS at 37"C for
30 min  and  then  washed in Hank's  buffer  without  calcium and
magnesium (Kantonsapotheke  Zurich, Switzerland). Thereafter, tar-
get cells were added to triplicate  samples of serial twofold dilutions
of NK92 cells in  round-bottom 96-well plates at  effector to target
(E:T) ratios ranging from 40:1 to 5:1. After  incubation for 4 hr, the
release of radioactive 51Cr  from labeled PED cells was analyzed  on a
gamma counter, and the percentage of specific lysis was calculated.
All  NK  cells, used as effectors, efficiently  lysed K562 cells, which
were used as  positive control targets. To calculate the mean percent-
age of inhibition  from four independent experiments, NK92-medi-
ated lysis of PED target cells with and without  prior DXS treatment
was compared at all four different E:T ratios. P values were deter-
mined by the Student paired t test.
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RESULTS
DXS Inhibits  All  Three  Pathways of Complement  Activation
Hemolytic  assays for  the  classic  (CH50),  alternative
(AP50), and lectin  (LP50) complement pathways were per-
formed to evaluate the efficacy  and specificity of complement
inhibition  by DXS. All complement  activation pathways were
dose-dependently  inhibited  by DXS. The concentrations at
which  50% inhibition  of the activities  was reached aC50)
were 0.12 mgtmL for the CH50 test, 0.10 mgtmL for the AP50
test, and 0.12 mgtmL for the LP50 test (Fig. 1).
DXS Dose-Dependently  Inhibits  Deposition of Human
Complement  on Pig Cells  and Cytotoxicity: Inhibition
Correlates  with Binding  of  DXS to the Cells
Pig  cells (PAEC and  PK15) were incubated  with  fresh
NHS,  and complement deposition was analyzed by FACS.
Preincubation of the cells with  different  concentrations of
DXS, followed by washing, resulted in a do~e-dependent  in-
hibition  of C3c deposition (Fig.  2A) with  an  IC50 of 1.2
mgtmL. Similar  results were obtained for the deposition of
C1q aC50=1.4  mgtmL)  and C4c  aC50=1.1  mgtmL). Parallel
to complement deposition, the cytotoxicity of human serum
against the porcine cells was dose-dependently  reduced from
52%:!:0.8% lysis  without  DXS to 18%:!:0.5%  lysis  with  25
mgtmL,  as  assessed by  propidium  iodide  staining.  No
changes  were observed  for deposition of human IgM and IgG
(data  not  shown). That  complement inhibition  correlated
with  an increased binding of DXS to the cells was shown by
using  DXS-Fluo, which bound  dose-dependently to PK15
r
FIGURE  1.  Dextran  sulfate  (DXS) inhibits  all  three  pathways
of complement  activation.  Hemolytic  assays for  the  classic
(CH50),  alternative  (AP50),  and  lectin  (LP50)  complement
pathways  were  performed  to evaluate  the  efficacy  and  spec-
ificity  of complement  inhibition.  DXS (.)  dose-dependently
inhibited  hemolysis  in  all  tests  (A: CH50, B:  AP50, C: LP50)
with  an  approximate  IC50  of 0.1  mg/mL.  Lysis  by  normal
human  serum  (NIlS)  without  addition  of  DXS (horizontal
lines  at 100%). Average  values  of  at least  three  experiments
with  indication  of the  standard  deviations.
cells and PAECs  (Fig.  2A). A significant  correlation  (r=0.95,
P<0.005  by  analysis  of  variance)  was  found  between  the
mean fluorescence  (MF) values  for C3c deposition  and  the log
(MF) values  for binding  of DXS-Fluo  (Fig. 2B). As determined
by live  and dead staining  (Molecular  Prooes  Europe,  Leiden,
The Netherlands),  incubation  of porcine  cells  with  DXS up to
a concentration  of 100 mg/mL  for 24 hr demonstrated  no toxic
effects on PAECs  or PK15  in vitro.
Time Course  of DXS-Mediated Endothelial  Cell Protection
In Vitro
To  evaluate  the  efficacy  of DXS-mediated  EC  protection
over  time,  PAECs  were  preincubated  with  DXS  (0.04-25
mg/mL)  for  30  min  and  then  washed.  Culturing  of the cells
was continued  under  normal  conditions  for  0  to 48 hr.  and841 September 15, 2003 LAUMONIER  ET AL.
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FIGURE  3.  Time course of DXS-mediated  endothelial  cell (EC)
protection.  Pig  aortic  ECs (PAECs) were  pretreated  with  DXS
(0.04-25 mg/mL) for  30 min,  and the  cell  culture  was contino
ued without  DXS. The cells  were  challenged  immediately  (8)
and  after  4 hr  (0), 24 hr  (8), and  48 hr  (0).  with  NHS and the
deposition  of C3c measured by FACS. To allow for comparison
of the MF values (y.axis)  obtained  at different  time points,  the
MF values measured without  DXS were  set to 1000/0.  Data  are
representative  for  three  experiments  with  similar  results.
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FIGURE  2.  Binding  of DXS to porcine cells correlates with
protection  from complement deposition. (A) Fluorescein-la-
beled DXS  (DXS-Fluo)  dose-dependently  bound to PK15 cells
(0) and inhibited  NHS-mediated C3c deposition (.)  as as-
sessed  by fluorescence-activated cell sorter (FACS)  analysis.
Averages of mean fluorescence (MF) values of three experi-
ments for DXS-FIuo binding  (0) and of seven  experiments for
C3c deposition (8),  with  standard deviations. (B) A signifi-
cant correlation  (r=O.95, P<O.OO5  by analysis of variance)
was found between the MF values for C3c  deposition and the
log (MF) for binding  of DXS-FIuo.
protection from  complement activation  on the  cell surface
was then tested by incubation of the cells with  NHS. DXS-
pretreated PAECs  were dose-dependently  protected from C3c
deposition with IC50 values of 0.7 mg/mL at 0 hr, 0.9 mg/mL
at 4 hr, 1.7  mg/mL at 24 hr, and 18 mg/mL at 48 hr after the
30-min DXS  incubation (Fig. 3). These  results show  that DXS
is  still  efficient in  protecting  pig cells from  deposition of
human  complement for up to 48 hr after treatment.
Increased  Binding  of  DXS-Fluv to Porcine  Aortic
Endothelial  Cells Pre  incubated with Normal Human Serum
or Heparinase-I
To see  whether binding of DXS to the EC surface  is favored
by release of HSPG from the cell surface,  PAECs were incu-
bated with human serum or heparinase as controls. Incuba-
tion  with NHS led  to a 44% decrease of FACS staining  for
HSPG, and after heparinase treatment, a reduction of 37%
was observed  (Fig. 4). Untreated PAECs and PAECs treated
with NHS or  heparinase were then incubated with DXS-Fluo
from  0.04 to 5 mg/mL. Compared with  untreated PAECs
(percentage  of F  ACS-positive cells at 5 mg DXS-Fluo/mL set
to  100%),  the binding  of DXS-Fluo  was dose-dependently
increased in  PAECs incubated  with  NHS (220% at 5 mg
DXS-Fluo/mL)  or heparinase (142%)  (Fig. 4)
DXS Inhibits Natural  Killer  Cell-Mediated  Xenogeneic
Cytotoxicity
To assess  the capacity of DXS to protect porcine  ECs from
not only complement-mediated  cytotoxicity but also NK cell-
mediated cytotoxicity, we tested NK92-mediated  lysis of  PED
in standard 51Cr  release assays (Fig. 5). The mean lysis  of
PED cells at the highest E:T ratio  of 40:  1 was 52.7%  in four
independent  experiments  (range 45.2%-61.0%)  at the lowest
E:T ratio  of 5:1, the mean lysis  still  reached  34.4%  (25.3%-
45.9%).  TNF-a stimulation ofPED enhanced  NK92-mediated
lysis  to 69.3% (60.6%-79.9%) at  a  40:1 ratio  and 57.3%
(45.5%-75.6%)  at a 5:1 ratio.  NK  cytotoxicity was signifi-
cantly reduced after treatment of PED with 25 mg/mL DXS
for 30 min before coincubation with  NK92 effector  cells (Fig.
5A). This protective effect of DXS was enhanced  when PED
cells  were  activated by serum deprivation (data not shown)  or
by TNF-a  stimulation  (Fig.  5B) before coincubation with
NK92 cells. The protective effect of DXS  was specific  for ECs
because  NK92-mediated lysis of K562 )Vas  not reduced  (Fig.
5C). When the mean percentage of inhibition  by DXS was
calculated from all four E:T ratios of four independent  exper-
iments, DXS treatment led to a 25.3% inhibition  (P<0.0001)
of NK92-mediated lysis, whereas  the mean percentage of
inhibition  by DXS  on NK92-mediated lysis of TNF  -a-stimu-
lated PED cells was 47.3% (P=0.0002).
DISCUSSION
It has been known for at least a decade  that low  MW DXS
is an efficient inhibitor of complement activation (15,  16,24).842 TRANSPLANTATION Vol. 76,  No.5
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FIGURE  4.  Increased  binding  of
DXS-F1uo to PAECs that were exper-
imentally  damaged.  P  AECs  were
preincubated  with  fresh NIlS  or he-
parinase-J  and  analyzed  by  FACS
for  surface  expression  of  heparan
sulfate  proteoglycan  (HSPG)  (col-
umns, MF value of untreated  PAECs
set to 1000/0).  In  parallel,  treated  and
untreated  PAECs  were-incubated
with  DXS-Fluo  (0.04-5  mg/mL),
washed,  and  analyzed  by  FACS to
quantify  the binding  of DXS to the
cells  (curves).  The  percentage  of
FACS-positive  cells  (MF>100)  for
untreated  PAECs  at  5  mg  DXS-
FluolmL  was  set to 100%.  Data  are
representative  of three independent
experiments  with  similar  results.
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Our  laboratory has shown that  DXS can prevent human
serum cytotoxicity against porcine cells in vitro  and hyper-
acute xenograft rejection in  an  ex vivo  pig lung  perfusion
model  (17). We therefore tested whether DXS  mainly acts as
a fluid-phase complement inhibitor  or whether it  can also
bind to the EC surface and provide direct protection to the
endothelium. In  the  present study, we showed that  DXS
inhibited  all three pathways of complement activation and
dose-dependently  protected pig cells from deposition of hu-
man complement,  and that  the EC-protective effect of DXS
correlated  with  binding  of  the  substance to the  cells. In
addition, we showed that  binding  of  DXS to porcine cells
increased after treatment  of the cells with  NHS or hepari-
nase. The latter finding indicates that  the release of HSPG
from the EC surface, as it is known to occur after activation
ofECs (e.g.,  by XNAs and complement)  <13),  favors the bind-
ing  of DXS. We therefore hypothesize that  DXS might  at
least functionally replace the shed HSPG on the EC surface
and thereby act as a "repair coat," preventing further damage
of  the cells by reestablishing  an  anticoagulant and anti-
inflammatory surface (Fig. 6).
In the xenotransplantation setting, EC activation is a cru-
cial  step in  the pathophysiology of A  VR, and  recent data
indicate that the classic complement pathway plays a major
role in human serum-induced activation of porcine ECs (25).
Because  transgenic (over)expression  of human complement
regulatory proteins on the surface of porcine ECs is able to
prevent HAR (b~t does not prevent subsequent  AVR), there
is still no efficient treatment available to date. The properties
of DXS described  in this  article, namely, the blocking of all
three pathways of complement activation and the preferen-
tial  binding to activated ECs that have lost their protective
layer of HSPG, indicate that  DXS might  be of use for the
treatment  of A  VR.  Therefore  DXS may  fill  a  gap in  our
current  armamentarium to fight  xenorejection. However, it
remains to be  determined by in vivo experiments whether the
known side effects  of DXS, mainly its  anticoagulant proper-
ties, will  preclude a clinical application. With the concept  of
reestablishing an anticoagulant and anti-inflammatory sur-
face (or "glycolandscape")  of the EC, after activation-induced
release of HSPG, we consider DXS a  prototype of an EC
protectant.  This  view is  supported  by  reports from other
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FIGURE  5.  DXS reduces natural  killer  (NK)92-mediated  cyto-
toxicity  against  porcine  ECs in  standard  51Cr release assays.
(A) PED cells were trypsinized,  incubated  with  25 mg/mL DXS
(white  symbols) or not (black  symbols),  and  then  used as tar-
get cells  for  NK92 effector  cells  at  four  different  effector  to
target  (E:T) ratios  ranging  from 40:1 to 5:1. (B) PED cells were
activated  by  treatment  with  twnor  necrosis  factor  (TNF)-a
(1'000 U/mL)  for  12 hr,  trypsinized,  incubated  with  25 mg/mL
DXS (white  symbols) or  not (black  symbols), and then  used as
target  cells.  (C) K562 cells were incubated  with  25 mg/mL DXS
(white  symbols) or not (black  symbols) and used as target cells
for  NK92 cells.  (A-C) One of four  independent  experiments.
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FIGURE  6.  Model for DXS-mediated
EC  protection.  (A)  Cellular  stress
leads to EC activation  and release of
HSPG (black)  from  the cell surface.
(B) "Bare"  (denuded)  ECs become a
privileged  target  for  mediators  of
innate  immunity,  such  as  comple-
ment  and  NK cells.  (C) DXS (gray)
can act as a "repair  coat"  and pro-
tect  ECs from damage.
~  ~~
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groups showing that DXS is able to protect cells from free
radical injury  (26).
NK cells are part of  the innate immune system  and as such
are involved in the early recognition and rejection of xeno-
grafts (11). We have shown that expression of human MHC
class I molecules on porcine EC reduces  xenogeneic  NK cell-
mediated cytotoxicity (27). However,  because  this protection
was only partial,  additional strategies are needed to protect
xenografts from NK cell-mediated damage. Indeed, as dem-
onstrated in the present study, DXS partially  inhibited  the
lysis of porcine EC by human NK cells. It was shown earlier
that the mouse NK cell receptor Ly49 (corresponding to the
human NKG2  family) binds to MHC  class I molecules and
acts as adhesion receptor. This interaction was inhibited  by
sulfated dextran MW 500'000  (50% inhibition  at 10-9 M) and
fucoidan,  whereas  several  other polysaccharides  of similar size
and negative  charge  showed  no effect  (28). DXS may thus mask
endothelialligands for NK activation receptors,  as supported  by
our findings that the protective effect of DXS is enhanced  on
activated endothelium,  and that NK cell-mediated  lysis of  stim-
ulated EC is reduced to the level of resting EC. Notably,  this
effect was specific for ECs because  lysis of the standard NK
target cell line K562 was not affected  by DXS.
We reported studies using in vitro  models. It  will  be im-
portant  to examine the capacity of  DXS to act as an EC
protectant in vivo. Our preliminary  results  in different ex-
perimental  models  are consistent with this likelihood.
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